Biocon shelled out billions to take control of the biosimilar joint venture it previously operated with Viatris, but deficiencies observed at several of its key manufacturing facilities continue to hold up US Food and Drug Administration approvals, dwindling further immediate returns on its investment.
In the latest of the company’s frustrations, Biocon has received a complete response letter from the agency rejecting approval for...






